Shu Jiang
About Shu Jiang
Shu Jiang serves as the Vice President of Finance at Organogenesis, a position he has held since 2023. With extensive experience in finance across various industries, he has previously worked in leadership roles at Curriculum Associates, Cytel, and Azurity Pharmaceuticals, and has completed numerous M&A transactions.
Work at Organogenesis
Shu Jiang has been serving as the Vice President of Finance at Organogenesis since 2023. In this role, Jiang is responsible for overseeing the financial operations and strategic financial planning of the company. Organogenesis specializes in regenerative medicine, and Jiang's expertise in finance is crucial for supporting the company's growth and operational efficiency.
Previous Experience in Finance
Before joining Organogenesis, Shu Jiang held the position of Vice President of Finance at Curriculum Associates from 2020 to 2023. Jiang also worked at Cytel as the Global Head of Finance for one year and served as Director of Finance at Azurity Pharmaceuticals. Additionally, Jiang has experience at Eliassen Group, where roles included Manager, Senior Analyst, and Analyst from 2013 to 2018.
Education and Expertise
Shu Jiang has an extensive educational background in finance and accounting. Jiang earned a Master's degree in Accounting from Bentley University and holds multiple Master's degrees in Finance from Suffolk University and Boston College Carroll School of Management. Jiang also completed Bachelor's degrees in Finance and Business from Nanyang Technological University Singapore and in Accounting and Finance from Xiamen University.
Advisory Role at The CFO Leadership Council
In addition to the role at Organogenesis, Shu Jiang has been an Advisory Board Member at The CFO Leadership Council since 2023. This position allows Jiang to contribute insights and expertise in finance, particularly in areas such as capital financing and IPO readiness, benefiting the broader CFO community.
M&A Transactions and Industry Experience
Shu Jiang has led and completed nine mergers and acquisitions (M&A) transactions, with values ranging from approximately $50 million to $6 billion. Jiang has industry experience across technology (SAAS), consulting, and healthcare/biotech/pharma sectors, and has worked with both private equity-owned and public companies.